LLS Research The Blood Cancer Answer. Deborah E. Banker, Ph.D. VP, Research Communications. Cures are the Answers we Seek. Survival rates have increased 2-4 fold over the last 40 years. The Research Challenge.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Deborah E. Banker, Ph.D.
VP, Research Communications
Survival rates have
increased 2-4 fold
over the last 40 years
$27M less to blood cancer research in 2007
Funding, in millions
LLS Research Funding
Philanthropy →Research → MoreCures
Research Grant Programs
Advances for patientsNOW!!
$5M in FY09 most relevant to pediatric blood cancers
(~ 20M total commitment)
FY09 Research Funding Distribution
CML - CP
Gleevec® - FDA approved 2001 for patients with newly diagnosed, chronic phase chronic myeloid leukemia (CML).
Velcade® -approved by FDA for myeloma patients in 2003.
Rituxan® - approved by FDA in 1997 for non-Hodgkin lymphoma (NHL) patients.
2003 – 2005: Dr.John Byrd and his LLS-funded team showed Rituxan + fludarabine (FR) is effective for newly diagnosed chronic lymphocytic leukemia (CLL) patients.
2001: Helen Anbinder diagnosed with CLL.
2008: Helen’s leukemia went active.
We’re not done until
100% of patients are cured or manage their diseases
with good quality of life.
There is not just one answer and many patients are still waiting for the one they need!